Who
David P. Southwell
Director
Company insider
Files Form 4 as: President and CEO, Rocket Pharmaceuticals; Director, PTC Therapeutics; Chief Executive Officer, TScan Therapeutics; Director, Spero Therapeutics; Chief Financial Officer, Human Genome Sciences; Director, THL Credit; Director, Biosphere Medical; Chief Financial Officer, Sepracor Inc /de/.
In numbers
- Trades disclosed
- 310
- Buys
- 14
- Sells
- 19
- Bought
- $842K
- Sold
- $11.0M
- Companies
- 8
- Companies where not an officer
- 4
- First trade
- 6 Dec 2005
- Last trade
- 3 Aug 2026
- Last filed
- 5 Aug 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 3 Aug 2026filed 5 Aug 2026 | RCKT Rocket PharmaceuticalsBiotechnology | SEC FORM 4 Code J | —150,000 at $0.00 | filing |
| 3 Aug 2026filed 5 Aug 2026 | RCKT Rocket PharmaceuticalsBiotechnology | SEC FORM 4 Code J | —150,000 at $0.00 | filing |
| 18 Jun 2026filed 6 Jul 2026 | RCKT Rocket PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —22,862 at $0.00 | filing |
| 18 Jun 2026filed 6 Jul 2026 | RCKT Rocket Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —64,860 at $0.00 | filing |
| 18 Jun 2026filed 6 Jul 2026 | RCKT Rocket Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —64,860 at $0.00 | filing |
| 18 Jun 2026filed 6 Jul 2026 | RCKT Rocket PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —22,862 at $0.00 | filing |
| 2 Jan 2026filed 6 Jan 2026 | PTCT PTC TherapeuticsBiotechnology | SEC FORM 4 Code A | —4,000 at $0.00 | filing |
| 2 Jan 2026filed 6 Jan 2026 | PTCT PTC Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —3,475 at $0.00 | filing |
| 2 Jan 2026filed 6 Jan 2026 | PTCT PTC Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —3,475 at $0.00 | filing |
| 2 Jan 2026filed 6 Jan 2026 | PTCT PTC TherapeuticsBiotechnology | SEC FORM 4 Code A | —4,000 at $0.00 | filing |
| 9 Sep 2025filed 11 Sep 2025 | PTCT PTC Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —12,000 at $0.00 | filing |
| 9 Sep 2025filed 11 Sep 2025 | PTCT PTC TherapeuticsBiotechnology | SEC FORM 4 Code M | $370K12,000 at $30.86 | filing |
| 9 Sep 2025filed 11 Sep 2025 | PTCT PTC TherapeuticsBiotechnology | SEC FORM 4 Sold | $700K12,000 at $58.34 | filing |
| 18 Jun 2025filed 18 Jul 2025 | RCKT Rocket PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —30,000 at $0.00 | filing |
| 3 Jan 2025filed 7 Jan 2025 | PTCT PTC Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —8,800 at $0.00 | filing |
| 3 Jan 2025filed 7 Jan 2025 | PTCT PTC TherapeuticsBiotechnology | SEC FORM 4 Code A | —4,000 at $0.00 | filing |
| 13 Jun 2024filed 20 Jun 2024 | RCKT Rocket Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —23,944 at $0.00 | filing |
| 8 May 2024filed 10 May 2024 | PTCT PTC TherapeuticsBiotechnology | SEC FORM 4 Code G | —1,650 at $0.00 | filing |
| 2 May 2024filed 20 May 2024 | RCKT Rocket PharmaceuticalsBiotechnology | SEC FORM 4 Code G | —113,124 at $0.00 | filing |
| 2 May 2024filed 20 May 2024 | RCKT Rocket PharmaceuticalsBiotechnology | SEC FORM 4 Code G | —59,716 at $0.00 | filing |
News
Alnylam Pharmaceuticals (NASDAQ:ALNY) and TScan Therapeutics (NASDAQ:TCRX) Critical SurveyTCRX · themarketsdaily.com · 20 Oct 2026PTC Therapeutics (NASDAQ:PTCT) & Aktis Oncology (NASDAQ:AKTS) Head to Head ContrastPTCT · dailypolitical.com · 19 Oct 2026PTC Therapeutics (NASDAQ:PTCT) Director Michael Schmertzler Sells 2,500 Shares of Company StockPTCT · tickerreport.com · 16 Oct 2026PTC Therapeutics (NASDAQ:PTCT) Stock: Insider Mark Elliott Boulding Sells 1,638 SharesPTCT · themarketsdaily.com · 9 Oct 2026Rocket Pharmaceuticals shares rise 4% after securing access to $150 million credit facilityRCKT · proactiveinvestors.com · 7 Oct 2026
0 headlines in the last 90 days name David P. Southwell; 5 articles from the last 14 days about the 3 companies they traded most, at most three about any one of them.